141 related articles for article (PubMed ID: 16570283)
1. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
[TBL] [Abstract][Full Text] [Related]
2. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
[TBL] [Abstract][Full Text] [Related]
3. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
[TBL] [Abstract][Full Text] [Related]
4. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
Gavrilyuk JI; Wuellner U; Barbas CF
Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
[TBL] [Abstract][Full Text] [Related]
5. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.
Trikha M; Zhou Z; Nemeth JA; Chen Q; Sharp C; Emmell E; Giles-Komar J; Nakada MT
Int J Cancer; 2004 Jun; 110(3):326-35. PubMed ID: 15095296
[TBL] [Abstract][Full Text] [Related]
6. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.
Trikha M; Zhou Z; Timar J; Raso E; Kennel M; Emmell E; Nakada MT
Cancer Res; 2002 May; 62(10):2824-33. PubMed ID: 12019160
[TBL] [Abstract][Full Text] [Related]
7. Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.
Li LS; Rader C; Matsushita M; Das S; Barbas CF; Lerner RA; Sinha SC
J Med Chem; 2004 Nov; 47(23):5630-40. PubMed ID: 15509162
[TBL] [Abstract][Full Text] [Related]
8. Breaking the one antibody-one target axiom.
Guo F; Das S; Mueller BM; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11009-14. PubMed ID: 16822849
[TBL] [Abstract][Full Text] [Related]
9. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.
Rader C; Sinha SC; Popkov M; Lerner RA; Barbas CF
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5396-400. PubMed ID: 12702756
[TBL] [Abstract][Full Text] [Related]
10. The disintegrin eristostatin interferes with integrin alpha 4 beta 1 function and with experimental metastasis of human melanoma cells.
Danen EH; Marcinkiewicz C; Cornelissen IM; van Kraats AA; Pachter JA; Ruiter DJ; Niewiarowski S; van Muijen GN
Exp Cell Res; 1998 Jan; 238(1):188-96. PubMed ID: 9457071
[TBL] [Abstract][Full Text] [Related]
11. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice.
Mitjans F; Sander D; Adán J; Sutter A; Martinez JM; Jäggle CS; Moyano JM; Kreysch HG; Piulats J; Goodman SL
J Cell Sci; 1995 Aug; 108 ( Pt 8)():2825-38. PubMed ID: 7593323
[TBL] [Abstract][Full Text] [Related]
12. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.
Natali PG; Hamby CV; Felding-Habermann B; Liang B; Nicotra MR; Di Filippo F; Giannarelli D; Temponi M; Ferrone S
Cancer Res; 1997 Apr; 57(8):1554-60. PubMed ID: 9108459
[TBL] [Abstract][Full Text] [Related]
14. An efficient chemical approach to bispecific antibodies and antibodies of high valency.
Gavrilyuk JI; Wuellner U; Salahuddin S; Goswami RK; Sinha SC; Barbas CF
Bioorg Med Chem Lett; 2009 Jul; 19(14):3716-20. PubMed ID: 19497743
[TBL] [Abstract][Full Text] [Related]
15. A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins alpha v beta 3, alpha v beta 5, and alpha v beta 6.
Lehmann M; Rabenandrasana C; Tamura R; Lissitzky JC; Quaranta V; Pichon J; Marvaldi J
Cancer Res; 1994 Apr; 54(8):2102-7. PubMed ID: 7513610
[TBL] [Abstract][Full Text] [Related]
16. Multiple catalytic aldolase antibodies suitable for chemical programming.
Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel cell binding site of periostin involved in tumour growth.
Orecchia P; Conte R; Balza E; Castellani P; Borsi L; Zardi L; Mingari MC; Carnemolla B
Eur J Cancer; 2011 Sep; 47(14):2221-9. PubMed ID: 21605971
[TBL] [Abstract][Full Text] [Related]
18. Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection.
Tanaka F; Fuller R; Shim H; Lerner RA; Barbas CF
J Mol Biol; 2004 Jan; 335(4):1007-18. PubMed ID: 14698295
[TBL] [Abstract][Full Text] [Related]
19. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
Mitjans F; Meyer T; Fittschen C; Goodman S; Jonczyk A; Marshall JF; Reyes G; Piulats J
Int J Cancer; 2000 Sep; 87(5):716-23. PubMed ID: 10925366
[TBL] [Abstract][Full Text] [Related]
20. The alpha 3 beta 1 integrin is involved in melanoma cell migration and invasion.
Melchiori A; Mortarini R; Carlone S; Marchisio PC; Anichini A; Noonan DM; Albini A
Exp Cell Res; 1995 Jul; 219(1):233-42. PubMed ID: 7628538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
